It sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide.
#Icad paris free#
The company sells its products to hospitals, ambulatory care centers, and free standing radiation oncology facilities. Further, it provides VeraLook that supports the detection of colonic polyps in conjunction with CT Colonography and the TotalLook MammoAdvantage system, a mammography specific digitizer. In addition, the company offers image analysis and workflow solutions in MRI imaging comprising SpectraLook for breast, VividLook for prostate, and OmniLook for other organs and VersaVue Enterprise, a review and reporting solution, which provides visual and quantitative depictions of the movement of contrast agent through a lesion. It also provides computer-aided detection (CAD) solutions for digital and film-based mammography systems, including SecondLook systems that detects and identifies masses and micro-calcifications and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to PACS and/or review workstations.
#Icad paris skin#
It offers Axxent eBx system, which is used for the treatment of early stage breast cancer, endometrial cancer, and skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated. provides image analysis, workflow solutions, and radiation therapy that enable healthcare professionals and radiologists to identify pathologies and pinpoint cancer earlier. Many of these cancers are diagnosed as interval breast cancers, defined as those that emerge after a normal mammogram but before the woman's next scheduled screening.ICAD, Inc. Regular, age-based mammography screening reduces breast cancer mortality by approximately 20%, but screening mammography can still miss 20 to 40% of breast cancers. This solution, now available for tomosynthesis, provides an accurate estimate of the risk of short-term breast cancer, which is truly personalized for each woman. In addition, the new version of ProFound AI Risk will also be available for demonstration at the iCAD booth at JFR. "By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall." "The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD's steadfast commitment to improving breast cancer detection for all women worldwide," said President Stacey Stevens. In addition, the company, based in Nashua, New Hampshire, will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Friday through Monday. ICAD to Take Wraps off Next Generation AI
0 kommentar(er)
